Mitsubishi UFJ Trust & Banking’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mitsubishi UFJ Trust & Banking’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Buy	+24,587	New	+$222K	﹤0.01%	1283

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

IMC Chicago Chicago, Illinois $419B AUM 72.04% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Mitsubishi UFJ Trust & Banking's BCRX Position: Q2 2026 in Review

Mitsubishi UFJ Trust & Banking opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 24,587 shares worth $246K. The stake represents ﹤0.01% of the portfolio and ranks #1283 among its holdings.

115 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Mitsubishi UFJ Trust & Banking held 24,587 shares of BioCryst Pharmaceuticals worth $246K as of Q2 2026.
BioCryst Pharmaceuticals was a new Mitsubishi UFJ Trust & Banking position in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Mitsubishi UFJ Trust & Banking's portfolio in Q2 2026, its #1283 holding.
115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Mitsubishi UFJ Trust & Banking's 13F filing for Q2 2026, filed 6 Aug 2026.